Establishment of new intraperitoneal paclitaxel-resistant gastric cancer cell lines and comprehensive gene expression analysis

Anticancer Research

Volumn 33, Issue 10, 2013, Pages 4299-4308

  Murakami, Hiroki ^a,b   Ito, Seiji ^a   Tanaka, Harunari ^a   Kondo, Eisaku ^a   Kodera, Yasuhiro ^b   Nakanishi, Hayao ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Gastric cancer cell lines; Gene expression profile; In vivo selection; Paclitaxel resistance; Peritoneal metastasis

Indexed keywords

AAA DOMAIN CONTAINING 2; ADENOSINE TRIPHOSPHATASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KINESIN; KINESIN FAMILY MEMBER 23; PACLITAXEL; PHD FINGER PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PERITONEUM METASTASIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; UPREGULATION;

GASTRIC CANCER CELL LINES; GENE EXPRESSION PROFILE; IN VIVO SELECTION; PACLITAXEL-RESISTANCE; PERITONEAL METASTASIS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOSINE TRIPHOSPHATASES; AGED; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL PROLIFERATION; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PACLITAXEL; PERITONEAL CAVITY; STOMACH NEOPLASMS; TRANSCRIPTOME; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84891366081     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Landry J, Tepper JE, Wood WC, Moulton EO, Koerner F and Sullinger J: Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Boil Phys 19: 1357-1362, 1990.
2. Dupont JB Jr., Lee JR, Burton GR and Cohn I Jr.: Adenocarcinoma of the stomach: Review of 1,497 cases. Cancer 41: 941-947, 1978.
3. Shitara K, Mizota A, Matsuo K, Sato Y, Kondo C, Takahari D, Ura T, Tajika M and Muro K: Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis. Gastric Cancer 16: 48-55, 2013.
4. Ajani JA, Ota DM, Jessup JM, Ames FC, McBride C, Boddie A, Levin B, Jackson DE, Roh M and Hohn D: Resectable gastric carcinoma: An evaluation of preoperative and postoperative chemotherapy. Cancer 68: 1501-1506, 1991.
5. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M and Kang YK: Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29: 3968-3976, 2011.
6. Ohashi N, Kodera Y, Nakanishi H, Yokoyama H, Fujiwara M, Koike M, Hibi K, Nakao A and Tatematsu M: Efficacy of intraperitoneal chemotherapy with paclitaxel targeting peritoneal micrometastasis as revealed by GFP-tagged human gastric cancer cell lines in nude mice. Int J Oncol 27: 637-644, 2005.
7. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL and Burger RA: Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34-43, 2006.
8. Kodera Y, Ito Y, Ito S, Ohashi N, Mochizuki Y, Yamamura Y, Koike M, Fujiwara M, Nakanishi H and Nakao A: Intraperitoneal paclitaxel: A possible impact of regional delivery for prevention of peritoneal carcinomatosis in patients with gastric carcinoma. Hepatogastroenterology 54: 960-963, 2007.
9. Ishigami H, Kitayama J, Kaisaki S, Yamaguchi H, Yamashita H, Emoto S and Nagawa H: Phase I study of biweekly intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel for gastric cancer with peritoneal metastasis. Oncology 79: 269-272, 2010.
10. Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, Kamei T, Soma D, Miyato H, Yamashita H and Nagawa H: Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol 21: 67-70, 2010.
11. Duan Z, Brakora KA and Seiden MV: Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther 3: 833-838, 2004.
12. Aoki D, Oda Y, Hattori S, Taguchi K, Ohishi Y, Basaki Y, Oie S, Suzuki N, Kono S, Tsuneyoshi M, Ono M, Yanagawa T and Kuwano M. Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma. Clin Cancer Res 15: 1473-1480, 2009.
13. Catuogno S, Cerchia L, Romano G, Pognonec P, Condorelli G and de Franciscis V: miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis. Oncogene 32: 341-351, 2013.
14. Zhang J, Zhao J, Zhang W, Liu G, Yin D, Li J, Zhang S and Li H: Establishment of paclitaxel-resistant cell line and the underlying mechanism on drug resistance. Int J Gynecol Cancer 22: 1450-1456, 2012.
15. Okugawa K, Kobayashi H, Hirakawa T, Sonoda T, Ogura T and Nakano H: In vivo establishment and characterization of a paclitaxel-resistant human avarian cancer cell line showing enhanced growth properties and drug-resistance only in vivo. J Cancer Res Clin Oncol 130: 178-186, 2004.
16. Murakami H, Nakanishi H, Tanaka H, Ito S, Misawa K, Ito Y, Ikehara Y, Kondo E and Kodera Y: Establishment and characterization of novel gastric signet-ring cell and non signet-ring cell poorly differentiated adenocarcinoma cell lines with low and high malignant potential. Gastric Cancer 16: 74-83, 2013.
17. Oshima Y, Tanaka H, Murakami H, Ito Y, Furuya T, Kondo E, Kodera Y and Nakanishi H: Lapatinib sensitivity of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines. Gastric Cancer, in press, 2013.
18. Zhang X, Yashiro M, Qiu H, Nishi T, Matsuzaki T and Hirakawa K: Establishment and Characterization of multidrug-resistant gastric cancer cell lines. Anticancer Res 30: 915-922, 2010.
19. Takahashi S, Fusaki N, Ohta S, Iwahori Y, Iizuka Y, Inagawa K, Kawakami Y, Yoshida K and Toda M: Down-regulation of KIF23 suppresses glioma proliferation. J Neurooncol 106: 519-529, 2012.
20. Fischer M, Grundke I, Sohr S, Quaas M, Hoffmann S, Knörck A, Gumhold C and Rother K: p53 and cell-cycle dependent transcription of kinesin family member 23 (KIF23) is controlled via a CHR promoter element bound by DREAM and MMB complexes. PLoS One 8: e63187, 2013.
21. Liu D, Shi M, Zhang H, Qian L, Yu M, Hu M, Zhang R, Wang T, Han C, Duan H and Guo N: c-Myb regulates cell cycle-dependent expression of Erbin: An implication for a novel function of Erbin. PLoS One 7: e42903, 2012.
22. Duan Z, Zou JX, Yang P, Wang Y, Borowsky AD, Gao AC and Chen HW: Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate via MLL histone methylase complex. Prostate 73: 455-466, 2013.
23. Ghislin S, Deshayes F, Middendorp S, Boggetto N and Alcaide-Loridan C: PHF19 and Akt control the switch between proliferative and invasive states in melanoma. Cell Cycle 11: 1634-1645, 2012.
24. Kim HK, Choi IJ, Kim CG, Kim HS, Oshima A, Michalowski A and Green JE: A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients. PLoS One 6: e16694, 2013.